Trends in aortic valve replacement for aortic stenosis: a French nationwide study.


Journal

European heart journal
ISSN: 1522-9645
Titre abrégé: Eur Heart J
Pays: England
ID NLM: 8006263

Informations de publication

Date de publication:
12 02 2022
Historique:
received: 22 04 2021
revised: 20 07 2021
accepted: 25 10 2021
entrez: 25 10 2022
pubmed: 26 10 2022
medline: 28 10 2022
Statut: ppublish

Résumé

Transcatheter aortic valve replacement (TAVR) as an alternative to surgical aortic valve replacement (SAVR) has profoundly changed the management of patients with aortic valve stenosis (AS). Large unbiased nationwide data regarding TAVR implementation, impact on SAVR and their respective outcomes are scarce. Based on a French administrative hospital-discharge database, we collected data on all consecutive aortic valve replacements (AVRs) performed in France for AS between 2007 and 2019 [106 253 isolated SAVR (49%), 46 514 combined SAVR (21%), and 65 651 TAVR (30%)]. The number of AVR linearly increased between 2007 and 2019 (from 10 892 to 23 109, P for trend < 0.0001) due to a marked increase in TAVR (from 253 to 13 030, P for trend < 0.0001), while SAVR increased up to 2013 and then declined (10 892 in 2007, 12 699 in 2013, and 10 079 in 2019). The Charlson index decreased linearly for TAVR, but in two steps for SAVR (2011 and 2017). In-hospital mortality rates of both SAVR and TAVR declined (both P for trend < 0.0001) and were similar or lower for TAVR than for isolated SAVR in patients 75 years or above in the last 3 years (2017-19). Complication rates of TAVR also declined but permanent pacemaker rates remained high and length of stay substantial (16.7% and median 6 days, respectively, in 2017-19). The number of AVR has doubled in a decade and TAVR has become the dominant form of AVR in 2018. The improvement in patient profiles seems to have anticipated the demonstrated benefit of TAVR in intermediate and low-risk patients. In patients 75 years or older, TAVR should be considered as the first option. We also highlight two important areas for improvement, the high permanent pacemaker rates, and the long length of stay even in the contemporary era. Our results may have major implications for clinical practice and policymakers.

Identifiants

pubmed: 36282793
pii: 6772766
doi: 10.1093/eurheartj/ehab773
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

666-679

Informations de copyright

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2021. For permissions, please email: journals.permissions@oup.com.

Auteurs

Virginia Nguyen (V)

Cardiology Department, Centre Cardiologique du Nord, Saint-Denis, France.

Nadav Willner (N)

Department of Cardiology, University of Ottawa Heart Institute, Ottawa, ON, Canada.

Helene Eltchaninoff (H)

Department of Cardiology, Normandie University, UNIROUEN, U1096, CHU Rouen, Rouen, F-76000 France.

Ian G Burwash (IG)

Department of Cardiology, University of Ottawa Heart Institute, Ottawa, ON, Canada.

Morgane Michel (M)

Université de Paris, Paris, France.
URC Eco Ile de France, AP-HP, Hôtel Dieu, Paris, France.
INSERM, ECEVE, U1123, Paris, France.

Eric Durand (E)

Department of Cardiology, Normandie University, UNIROUEN, U1096, CHU Rouen, Rouen, F-76000 France.

Martine Gilard (M)

Department of Cardiology, Brest University Hospital, Brest, France.

Christel Dindorf (C)

Department of Cardiology, Normandie University, UNIROUEN, U1096, CHU Rouen, Rouen, F-76000 France.
Université de Paris, Paris, France.
URC Eco Ile de France, AP-HP, Hôtel Dieu, Paris, France.

Bernard Iung (B)

Université de Paris, Paris, France.
Department of Cardiology, Assistance Publique-Hôpitaux de Paris (AP-HP), Bichat Hospital, Paris, France.
INSERM U1148, Bichat Hospital, Paris, France.

Alain Cribier (A)

Department of Cardiology, Normandie University, UNIROUEN, U1096, CHU Rouen, Rouen, F-76000 France.

Alec Vahanian (A)

Université de Paris, Paris, France.
INSERM U1148, Bichat Hospital, Paris, France.

Karine Chevreul (K)

Université de Paris, Paris, France.
URC Eco Ile de France, AP-HP, Hôtel Dieu, Paris, France.
INSERM, ECEVE, U1123, Paris, France.

David Messika-Zeitoun (D)

Department of Cardiology, University of Ottawa Heart Institute, Ottawa, ON, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH